Company intelligence / Profile preview

Basilard BioTech

Riverside or Southern California region, California, United States

Ownership: Private
Development stage: Preclinical

Overview

Basilard BioTech has developed Celletto™, a disruptive nanomechanical gene delivery platform that achieves high cellular viability and transfection efficiency—reportedly exceeding current leading solutions by up to 400%. The company’s approach aims to overcome the limitations of viral vectors and other nonviral methods in cell and gene therapy manufacturing. No direct clinical results reported as the company provides enabling technology rather than therapeutics[1][5].

Therapeutic areas: Other
Modalities: Gene delivery (nonviral, nanomechanical/mechanoporation)Cell-based therapies (enabling technology)
Industry: Non-Drug Biotech

Partnerships

Paladin Capital Group (investor/private equity owner)[2]

Beyond the preview

Go deeper on Basilard BioTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Basilard BioTech.

Explore the full profile